Shillong Herald

Respiratory Syncytial Virus Pipeline Landscape Analysis: 50+ Key Players & 50+ Pipeline Drugs

 Breaking News
  • No posts were found

Respiratory Syncytial Virus Pipeline Landscape Analysis: 50+ Key Players & 50+ Pipeline Drugs

November 17
19:48 2022
Respiratory Syncytial Virus Pipeline Landscape Analysis: 50+ Key Players & 50+ Pipeline Drugs

DelveInsight’s, “Respiratory Syncytial Virus Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Respiratory Syncytial Virus (RSV) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Respiratory Syncytial Virus Pipeline Insight report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Respiratory Syncytial Virus (RSV) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Respiratory Syncytial Virus Pipeline Report

  • DelveInsight’s Respiratory Syncytial Virus Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
  • The leading Respiratory Syncytial Virus Companies are working such as Ark Biosciences, Enanta Pharmaceuticals, Virometix, Codagenix, Inc., Daiichi Sankyo Company, Meissa Vaccines, Inc., Advaccine (Suzhou) Biopharmaceuticals Co., Ltd., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, and others,
  • Promising Respiratory Syncytial Virus Pipeline therapies such as AK0611, EDP-323,V-306, CodaVax-RSV, VN-0200, MV-012-968, BARS13, EDP-938, MEDI8897, GSK 3888550A, RSVpreF, JNJ-53718678, and others.
  • The Respiratory Syncytial Virus Companies and academics are working to assess challenges and seek opportunities that could influence Respiratory Syncytial Virus (RSV) R&D. The therapies under development are focused on novel approaches to treat/improve Respiratory Syncytial Virus (RSV).

 

Recent Developmental Activities in the Respiratory Syncytial Virus Pipeline

  • This candidate vaccine contains a recombinant subunit pre-fusion RSV antigen (RSVPreF3) combined with GSK’s proprietary AS01 adjuvant, which is also used in GSK’s shingles vaccine. Currently, it is in phase III of development stage for the treatment of Respiratory Syncytial Virus (RSV).
  • MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the most prevalent cause of LRTI among infants and young children. Currently, it is in phase III of development stage.
  • Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting RSV F-mediated fusion of RSV with the host cell. Preclinical tests showed sisunatovir to have an excellent toxicity profile with an attractive therapeutic index. In Phase 1 clinical studies, sisunatovir showed excellent exposure with no serious adverse events being reported. In 2018, results from a Phase 2a challenge study in healthy adult volunteers were reported in which sisunatovir produced statistically significant reductions in viral load and clinical symptoms. ReViral has initiated two international multicentre Phase 2 clinical studies of sisunatovir in pediatric and adult high-risk patient populations.

 

Request a sample and discover the recent advances in Respiratory Syncytial Virus Medication @ Respiratory Syncytial Virus Clinical Trials Analysis

 

Respiratory Syncytial Virus Overview

Respiratory syncytial virus (RSV) is a very common cause of respiratory tract infection, particularly in children. Nearly all children have been infected by age 4 years, many in the first year of life. Infection does not provide complete immunity, so reinfection is common, although usually less serious. Outbreaks typically occur in winter and early spring. RSV is the most common cause of lower respiratory tract illness in young infants and is responsible for more than 50,000 hospitalizations every year in the United States in children under the age of 5 years. The first infection often progresses from an upper respiratory tract illness with congestion and fever to involve the lower respiratory tract, most commonly causing bronchiolitis and sometimes pneumonia with cough and difficulty breathing. Later infections usually involve only the upper respiratory tract. Children who have had bronchiolitis are more likely to be diagnosed with asthma when they are older.

 

Respiratory Syncytial Virus Emerging Drugs

  • GSK3844766A: GlaxoSmithKline
  • Nirsevimab (MEDI-8897): MedImmune
  • Sisunatovir: ReViral

 

Respiratory Syncytial Virus Pipeline Therapeutic Analysis

There are approx. 50+ key companies which are developing the therapies for Respiratory Syncytial Virus (RSV). The companies which have their Respiratory Syncytial Virus (RSV) drug candidates in the most advanced stage, i.e. phase III include, GlaxoSmithKline.

 

Learn more about the emerging Respiratory Syncytial Virus pipeline therapies @ Respiratory Syncytial Virus Treatment Landscape

 

Scope of the Respiratory Syncytial Virus Pipeline Report

  • Coverage- Global
  • Respiratory Syncytial Virus Pipeline Assessment by Product Type
  • Respiratory Syncytial Virus Pipeline Assessment by Stage and Product Type
  • Respiratory Syncytial Virus Pipeline Assessment by Route of Administration
  • Respiratory Syncytial Virus Pipeline Assessment by Stage and Route of Administration
  • Respiratory Syncytial Virus Pipeline Assessment by Molecule Type
  • Respiratory Syncytial Virus Pipeline Assessment by Stage and Molecule Type
  • Respiratory Syncytial Virus Companies- Ark Biosciences, Enanta Pharmaceuticals, Virometix, Codagenix, Inc., Daiichi Sankyo Company, Meissa Vaccines, Inc., Advaccine (Suzhou) Biopharmaceuticals Co., Ltd., Enanta Pharmaceuticals, MedImmune LLC (AstraZeneca), GlaxoSmithKline, Pfizer, Janssen Sciences Ireland UC, and others.
  • Respiratory Syncytial Virus Pipeline Therapies- AK0611, EDP-323,V-306, CodaVax-RSV, VN-0200, MV-012-968, BARS13, EDP-938, MEDI8897, GSK 3888550A, RSVpreF, JNJ-53718678, and others

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Respiratory Syncytial Virus (RSV): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Respiratory Syncytial Virus (RSV) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Respiratory Syncytial Virus (RSV) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. GSK3844766A: GlaxoSmithKline
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. EDP 938: Enanta Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. mRNA-1345: Moderna Therapeutics
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. AR-201: Aridis Pharmaceuticals
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Respiratory Syncytial Virus (RSV) Key Companies
  23. Respiratory Syncytial Virus (RSV) Key Products
  24. Respiratory Syncytial Virus (RSV)- Unmet Needs
  25. Respiratory Syncytial Virus (RSV)- Market Drivers and Barriers
  26. Respiratory Syncytial Virus (RSV)- Future Perspectives and Conclusion
  27. Respiratory Syncytial Virus (RSV) Analyst Views
  28. Respiratory Syncytial Virus (RSV) Key Companies
  29. Appendix

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Respiratory Syncytial Virus (RSV) drugs?
  • How many Respiratory Syncytial Virus (RSV) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Respiratory Syncytial Virus (RSV)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Respiratory Syncytial Virus (RSV) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Respiratory Syncytial Virus (RSV) and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

For more information about the Respiratory Syncytial Virus Pipeline Outlook Report @ Respiratory Syncytial Virus Pipeline Drugs

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles